503 related articles for article (PubMed ID: 34509667)
21. Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles.
Yu KR; Natanson H; Dunbar CE
Hum Gene Ther; 2016 Oct; 27(10):729-740. PubMed ID: 27483988
[TBL] [Abstract][Full Text] [Related]
22. Editing human hematopoietic stem cells: advances and challenges.
Bhoopalan SV; Yen JS; Levine RM; Sharma A
Cytotherapy; 2023 Mar; 25(3):261-269. PubMed ID: 36123234
[TBL] [Abstract][Full Text] [Related]
23. In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations.
Psatha N; Paschoudi K; Papadopoulou A; Yannaki E
Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553489
[TBL] [Abstract][Full Text] [Related]
24. Gene editing and its application for hematological diseases.
Osborn MJ; Belanto JJ; Tolar J; Voytas DF
Int J Hematol; 2016 Jul; 104(1):18-28. PubMed ID: 27233509
[TBL] [Abstract][Full Text] [Related]
25. Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy.
Ferrari S; Valeri E; Conti A; Scala S; Aprile A; Di Micco R; Kajaste-Rudnitski A; Montini E; Ferrari G; Aiuti A; Naldini L
Cell Stem Cell; 2023 May; 30(5):549-570. PubMed ID: 37146580
[TBL] [Abstract][Full Text] [Related]
26. Gene Editing: Regulatory and Translation to Clinic.
Ando D; Meyer K
Hematol Oncol Clin North Am; 2017 Oct; 31(5):797-808. PubMed ID: 28895848
[TBL] [Abstract][Full Text] [Related]
27. Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for
Dudek AM; Porteus MH
Front Immunol; 2021; 12():660302. PubMed ID: 34122418
[TBL] [Abstract][Full Text] [Related]
28. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
29. Engineering Delivery Vehicles for Genome Editing.
Nelson CE; Gersbach CA
Annu Rev Chem Biomol Eng; 2016 Jun; 7():637-62. PubMed ID: 27146557
[TBL] [Abstract][Full Text] [Related]
30. Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates.
Peterson CW; Wang J; Norman KK; Norgaard ZK; Humbert O; Tse CK; Yan JJ; Trimble RG; Shivak DA; Rebar EJ; Gregory PD; Holmes MC; Kiem HP
Blood; 2016 May; 127(20):2416-26. PubMed ID: 26980728
[TBL] [Abstract][Full Text] [Related]
31. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
Eid A; Mahfouz MM
Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in genome editing of stem cells for drug discovery and therapeutic application.
Lee J; Bayarsaikhan D; Bayarsaikhan G; Kim JS; Schwarzbach E; Lee B
Pharmacol Ther; 2020 May; 209():107501. PubMed ID: 32061705
[TBL] [Abstract][Full Text] [Related]
33. Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells.
Omer-Javed A; Pedrazzani G; Albano L; Ghaus S; Latroche C; Manzi M; Ferrari S; Fiumara M; Jacob A; Vavassori V; Nonis A; Canarutto D; Naldini L
Cell; 2022 Jun; 185(13):2248-2264.e21. PubMed ID: 35617958
[TBL] [Abstract][Full Text] [Related]
34. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
[TBL] [Abstract][Full Text] [Related]
35. Non-viral delivery of genome-editing nucleases for gene therapy.
Wang M; Glass ZA; Xu Q
Gene Ther; 2017 Mar; 24(3):144-150. PubMed ID: 27797355
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas9 genome editing in human hematopoietic stem cells.
Bak RO; Dever DP; Porteus MH
Nat Protoc; 2018 Feb; 13(2):358-376. PubMed ID: 29370156
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
38. Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells.
Vavassori V; Ferrari S; Beretta S; Asperti C; Albano L; Annoni A; Gaddoni C; Varesi A; Soldi M; Cuomo A; Bonaldi T; Radrizzani M; Merelli I; Naldini L
Blood; 2023 Aug; 142(9):812-826. PubMed ID: 37294917
[TBL] [Abstract][Full Text] [Related]
39. Genome-editing Technologies for Gene and Cell Therapy.
Maeder ML; Gersbach CA
Mol Ther; 2016 Mar; 24(3):430-46. PubMed ID: 26755333
[TBL] [Abstract][Full Text] [Related]
40. Applications of Genome Editing Tools in Stem Cells Towards Regenerative Medicine: An Update.
Kues WA; Kumar D; Selokar NL; Talluri TR
Curr Stem Cell Res Ther; 2022; 17(3):267-279. PubMed ID: 34819011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
